WallStSmart

PepsiCo Inc (PEP)vsArcadia Biosciences Inc (RKDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

PepsiCo Inc generates 2041704% more annual revenue ($96.90B vs $4.75M). PEP leads profitability with a 10.8% profit margin vs -234.5%. PEP earns a higher WallStSmart Score of 71/100 (B).

PEP

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 8.0Value: 6.7Quality: 4.0
Piotroski: 3/9Altman Z: 2.26

RKDA

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.0Quality: 5.3
Piotroski: 3/9Altman Z: -58.76
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PEPUndervalued (+2.6%)

Margin of Safety

+2.6%

Fair Value

$139.91

Current Price

$136.32

$3.59 discount

UndervaluedFair: $139.91Overvalued
RKDAUndervalued (+24.4%)

Margin of Safety

+24.4%

Fair Value

$2.30

Current Price

$0.43

$1.87 discount

UndervaluedFair: $2.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PEP5 strengths · Avg: 9.0/10
Return on EquityProfitability
47.5%10/10

Every $100 of equity generates 47 in profit

EPS GrowthGrowth
137.0%10/10

Earnings expanding 137.0% YoY

Market CapQuality
$186.21B9/10

Large-cap with strong market position

P/E RatioValuation
17.9x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.50B8/10

Generating 1.5B in free cash flow

RKDA2 strengths · Avg: 9.0/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

EPS GrowthGrowth
28.5%8/10

Earnings expanding 28.5% YoY

Areas to Watch

PEP3 concerns · Avg: 2.7/10
Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Debt/EquityHealth
2.411/10

Elevated debt levels

RKDA4 concerns · Avg: 2.5/10
Market CapQuality
$1.14M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-323.1%2/10

ROE of -323.1% — below average capital efficiency

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : PEP

The strongest argument for PEP centers on Return on Equity, EPS Growth, Market Cap. PEG of 1.40 suggests the stock is reasonably priced for its growth.

Bull Case : RKDA

The strongest argument for RKDA centers on Price/Book, EPS Growth.

Bear Case : PEP

The primary concerns for PEP are Price/Book, Piotroski F-Score, Debt/Equity. Debt-to-equity of 2.41 is elevated, increasing financial risk.

Bear Case : RKDA

The primary concerns for RKDA are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

PEP profiles as a value stock while RKDA is a turnaround play — different risk/reward profiles.

RKDA carries more volatility with a beta of 0.53 — expect wider price swings.

PEP is growing revenue faster at 6.4% — sustainability is the question.

PEP generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

PEP scores higher overall (71/100 vs 36/100). RKDA offers better value entry with a 24.4% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

PepsiCo Inc

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

PepsiCo, Inc. is an American based multinational food, snack, and beverage corporation headquartered in Harrison, New York, in the hamlet of Purchase. PepsiCo's business encompasses all aspects of the food and beverage market. It oversees the manufacturing, distribution, and marketing of its products.

Arcadia Biosciences Inc

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Arcadia Biosciences, Inc. is dedicated to developing various crop productivity traits primarily in hemp, wheat, and soybeans. The company is headquartered in Davis, California.

Visit Website →

Want to dig deeper into these stocks?